Item 7.01. Regulation FD Disclosure.

Story continues below

The information in this Current Report (including Exhibit99.1) is being furnished and shall not be deemed “filed” for the purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Securities Exchange Act of 1934”), or otherwise subject to the liabilities of that Section. The information in this Current Report (including Exhibit99.1) shall not be incorporated by reference into any registration statement or other document to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

On August8, 2017, Theravance Biopharma,Inc. (the “Company”) issued a press release announcing early evidence of localized target engagement from the first cohort of the Company’s ongoing Phase 1b clinical trial of TD-1473 in patients with moderate to severe active ulcerative colitis. A copy of the press release is filed as Exhibit99.1 hereto and incorporated by reference into this Current Report on Form8-K. A copy of the press release is furnished as Exhibit99.1 to this report and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.


99.1 Press Release Dated August8, 2017

Theravance Biopharma, Inc. Exhibit
EX-99.1 2 a17-19129_1ex99d1.htm EX-99.1 Exhibit 99.1     Theravance Biopharma Reports Encouraging Data from First Cohort of Patients in Phase 1b Clinical Trial of TD-1473 in Ulcerative Colitis   Evidence of Localized Target Engagement after Four Weeks of Treatment Minimal Systemic Exposure No Evidence of Systemic Immunosuppression or Infections   Company Plans to Progress TD-1473 into Induction and Maintenance Study in 2018   DUBLIN,…
To view the full exhibit click here


Theravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. Its commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease. Its neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases.

An ad to help with our costs